Search results
-
ASH 2023 – a short-lived success for Poseida
ASH 2023 – a short-lived success for Poseida …
- 12/12/2023 - 01:08 -
ASH 2023 – Incyte hopes to add axatilimab to the arsenal
ASH 2023 – Incyte hopes to add axatilimab to the arsenal … Axatilimab Anti-CSF-1R Mab Syndax/ Incyte ASH 2023: 74% ORR at lowest dose in ≥3L chronic GvHD in …
- 12/12/2023 - 01:09 -
ASH 2023 – lacutamab’s late-line promise on hold
ASH 2023 – lacutamab’s late-line promise on hold …
- 12/10/2023 - 22:45 -
ASH 2023 – sense and serendipity in Dizal's Jackpot win
ASH 2023 – sense and serendipity in Dizal's Jackpot win …
- 12/11/2023 - 22:05 -
ASH 2023 – a new EZ battle shapes up
ASH 2023 – a new EZ battle shapes up … Cross-trial comparison of EZH1/2 inhibitors at ASH 2023 Company Daiichi Sankyo Haihe … TRAE leading to death 0% 3% Source: ASH 2023. On the face of it HH2853 looks slightly …
- 01/10/2024 - 18:06 -
ASH 2023 – lupus target could work in lymphoma too
ASH 2023 – lupus target could work in lymphoma too …
- 12/10/2023 - 22:44 -
ASH 2023 – Bristol follows in Talvey’s slipstream
ASH 2023 – Bristol follows in Talvey’s slipstream …
- 12/19/2023 - 10:16 -
ASH 2023 – Novartis sees early TIM-3 promise
ASH 2023 – Novartis sees early TIM-3 promise …
- 12/10/2023 - 22:45 -
ASH 2023 – the search for a better Ayvakit
ASH 2023 – the search for a better Ayvakit …
- 12/15/2023 - 15:21 -
ASH 2023 – J&J makes menin a three-horse race
ASH 2023 – J&J makes menin a three-horse race … febrile neutropenia Not given Source ASH 2023 ASH 2022 2 Oct 2023 event/ ASH 2023 abstract EHA 2023 Notes: *the …
- 01/10/2024 - 17:43
